Monday, September 24, 2012

Spectrum DD Links (anecdotal)


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

Folotyn with Fusilev for treating Mucositis
http://www.youtube.com/watch?v=PhLw2q9FjzE

Zevalin
http://www.youtube.com/watch?v=mpFH6yeHn1U
http://www.youtube.com/watch?v=HIyuSPdU_mc&feature=related
http://www.youtube.com/watch?v=Ju18lscaRxo
http://www.lymphomainfo.net/news/studies-and-trials/zevalin-hits-high-notes-at-2011-lymphoma-conference
http://treato.com/zevalin/?a=s  (some promising patient testaments on Zevalin)
http://www.webmd.com/drugs/drugreview-63685-Zevalin%20In-111%20IV.aspx?drugid=63685&drugname=Zevalin%20(In-111)%20IV
http://www.nytimes.com/2007/07/14/health/14lymphoma.html?pagewanted=prints (why Zevalin sales have been low)
http://www.lymphoma.org/site/apps/s/content.asp?c=bkLTKaOQLmK8E&b=6298135&ct=8730669
http://www.betsydeparry.com/radioimmunotherapy.html
http://csn.cancer.org/node/187871
http://www.lymphomation.org/-story-Jan.htm
http://discoverysedge.mayo.edu/charlottes_story/index.cfm
http://www.imakenews.com/barnesreport/e_article000981938.cfm
https://ash.confex.com/ash/2011/webprogram/Paper37317.html  (zevalin clinical trial)
http://voicesofsurvivors.org/?p=1198



If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.

Saturday, September 22, 2012

Why Topotarget was overzealous in releasing preliminary top-line data from the Belief trial ?


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

Here are some quotes (google translated-Not a good translation) from this article in a danish financial newspaper.


http://borsen.dk/nyheder/investor/artikel/1/241624/topotarget_stiger_140_pct_efter_belinostat-succes.html
http://www.bioworld.com/content/topotarget-hdac-bulls-eye-spectrum-benefit-ahead-0

QUOTE

"He points out that the results means that now can really boost the company's strategic deliberations on possible divestment. Topotarget prayed for a good three weeks ago trading house ABG Sundal Collier to investigate and advise on opportunities. "

He says that Topotarget not have written off the possibility for them to raise money. 
"But we have no hurry. You might as well explore all options before making a decision. True, it is based on a presentation by ABG to the Board, which then must discuss it," says Anders Vadsholt. 

QUOTE

Why the Belinostat Belief trial is likely headed for success ?
QUOTE
Although a few of the study 129 patients still on treatment, and yet a lack of data on how the treatment has worked on them, it can be stated that the primary objective of an objective response rate of 20 per cent. is reached. 
"The fact that we see that we are already reaches 20 per cent., Makes me really, really happy," says CEO Anders Vadsholt Ritzau Finance. 

The economic penetrated biotech company said although on that occasion a partnership agreement for Belinostat outside the U.S. partner Spectrum's area, a merger with an industrial partner or an outright sale of the company. 
"What is our challenge, our capital base means we can not just kick a whole lot of new studies in progress, which you probably should do when you start to get these data, we are now," explains Anders Vadsholt. 

QUOTE

If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.

Tuesday, September 4, 2012

Amarin's - Approved MARINE Patent claims


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

This is one big step towards protecting exclusivity of VASCEPA. The patent claims on TG & Apo-B reduction, LDL neutrality as well as non-HDL, Lp-Pla2 reduction. This patent is for the marine(500-2000mg/dl TG) indication.

Marine Patent claims-> Link

If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.